Literature DB >> 11232196

Mechanisms of cholestasis.

G A Kullak-Ublick1, P J Meier.   

Abstract

From the multiple mechanisms of cholestasis presented in this article, a unifying hypothesis may be deduced by parsimony. The disturbance of the flow of bile must inevitably lead to the intracellular retention of biliary constituents. Alternatively, the lack of specific components of bile unmasks the toxic potential of other components, as in the case of experimental mdr2 deficiency. In the sequence of events that leads to liver injury, the cytotoxic action of bile salts is pivotal to all forms of cholestasis. The inhibition of the bsep by drugs, sex steroids, or monohydroxy bile salts is an example of direct toxicity to the key mediator in canalicular bile salt excretion. In other syndromes, the dysfunction of distinct hepatocellular transport systems is the primary pathogenetic defect leading to cholestasis. Such dysfunctions include the genetic defects in PFIC and the direct inhibition of gene transcription by cytokines. Perturbations in the short-term regulation of transport protein function are exemplified by the cholestasis of endotoxinemia. The effect of bile salts on signal transduction, gene transcription, and transport processes in hepatocytes and cholangiocytes has become the focus of intense research in recent years. The central role of bile salts in the pathogenesis of cholestasis has, ironically, become all the more evident from the improvement of many cholestatic syndromes with oral bile salt therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11232196     DOI: 10.1016/s1089-3261(05)70114-8

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  26 in total

1.  Critical Factors in the Assessment of Cholestatic Liver Injury In Vitro.

Authors:  Benjamin L Woolbright; Hartmut Jaeschke
Journal:  Methods Mol Biol       Date:  2015

2.  Cholesterol detoxification by the nuclear pregnane X receptor.

Authors:  Steven A Kliewer
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-14       Impact factor: 11.205

Review 3.  Calcium signaling in the liver.

Authors:  Maria Jimena Amaya; Michael H Nathanson
Journal:  Compr Physiol       Date:  2013-01       Impact factor: 9.090

4.  Hepatic pharmacokinetics of taurocholate in the normal and cholestatic rat liver.

Authors:  Daniel Y Hung; Gerhard A Siebert; Ping Chang; Michael S Roberts
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

5.  Non-invasive urinary metabolomic profiles discriminate biliary atresia from infantile hepatitis syndrome.

Authors:  Wei-Wei Li; Yan Yang; Qi-Gang Dai; Li-Li Lin; Tong Xie; Li-Li He; Jia-Lei Tao; Jin-Jun Shan; Shou-Chuan Wang
Journal:  Metabolomics       Date:  2018-06-21       Impact factor: 4.290

6.  Bile acid-induced necrosis in primary human hepatocytes and in patients with obstructive cholestasis.

Authors:  Benjamin L Woolbright; Kenneth Dorko; Daniel J Antoine; Joanna I Clarke; Parviz Gholami; Feng Li; Sean C Kumer; Timothy M Schmitt; Jameson Forster; Fang Fan; Rosalind E Jenkins; B Kevin Park; Bruno Hagenbuch; Mojtaba Olyaee; Hartmut Jaeschke
Journal:  Toxicol Appl Pharmacol       Date:  2015-01-28       Impact factor: 4.219

7.  Hepatic damage in biliary-obstructed rats is ameliorated by leflunomide treatment.

Authors:  Abdurrahman Karaman; Mustafa Iraz; Hale Kirimlioglu; Nese Karadag; Erkan Tas; Ersin Fadillioglu
Journal:  Pediatr Surg Int       Date:  2006-08-05       Impact factor: 1.827

8.  Erdosteine treatment attenuates oxidative stress and fibrosis in experimental biliary obstruction.

Authors:  Göksel Sener; A Ozer Sehirli; Hale Z Toklu; Meral Yuksel; Feriha Ercan; Nursal Gedik
Journal:  Pediatr Surg Int       Date:  2007-01-10       Impact factor: 1.827

9.  Transport of bile acids in multidrug-resistance-protein 3-overexpressing cells co-transfected with the ileal Na+-dependent bile-acid transporter.

Authors:  Noam Zelcer; Tohru Saeki; Ilse Bot; Annemieke Kuil; Piet Borst
Journal:  Biochem J       Date:  2003-01-01       Impact factor: 3.857

10.  Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats.

Authors:  Craig D Fisher; Andrew J Lickteig; Lisa M Augustine; Ronald P J Oude Elferink; David G Besselsen; Robert P Erickson; Nathan J Cherrington
Journal:  Eur J Pharmacol       Date:  2009-04-07       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.